Cargando…

Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers

BACKGROUND: The rational use of antibiotics is one of the main strategies to limit the development of bacterial resistance. We therefore sought to evaluate the effectiveness of a C-reactive protein-based protocol in reducing antibiotic treatment time in critically ill patients. METHODS: A randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Borges, Isabela, Carneiro, Rafael, Bergo, Rafael, Martins, Larissa, Colosimo, Enrico, Oliveira, Carolina, Saturnino, Saulo, Andrade, Marcus Vinícius, Ravetti, Cecilia, Nobre, Vandack
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266125/
https://www.ncbi.nlm.nih.gov/pubmed/32487263
http://dx.doi.org/10.1186/s13054-020-02946-y
_version_ 1783541245069492224
author Borges, Isabela
Carneiro, Rafael
Bergo, Rafael
Martins, Larissa
Colosimo, Enrico
Oliveira, Carolina
Saturnino, Saulo
Andrade, Marcus Vinícius
Ravetti, Cecilia
Nobre, Vandack
author_facet Borges, Isabela
Carneiro, Rafael
Bergo, Rafael
Martins, Larissa
Colosimo, Enrico
Oliveira, Carolina
Saturnino, Saulo
Andrade, Marcus Vinícius
Ravetti, Cecilia
Nobre, Vandack
author_sort Borges, Isabela
collection PubMed
description BACKGROUND: The rational use of antibiotics is one of the main strategies to limit the development of bacterial resistance. We therefore sought to evaluate the effectiveness of a C-reactive protein-based protocol in reducing antibiotic treatment time in critically ill patients. METHODS: A randomized, open-label, controlled clinical trial conducted in two intensive care units of a university hospital in Brazil. Critically ill infected adult patients were randomly allocated to (i) intervention to receive antibiotics guided by daily monitoring of CRP levels and (ii) control to receive antibiotics according to the best practices for rational use of antibiotics. RESULTS: One hundred thirty patients were included in the CRP (n = 64) and control (n = 66) groups. In the intention-to-treat analysis, the median duration of antibiotic therapy for the index infectious episode was 7.0 (5.0–8.8) days in the CRP and 7.0 (7.0–11.3) days in the control (p = 0.011) groups. A significant difference in the treatment time between the two groups was identified in the curve of cumulative suspension of antibiotics, with less exposure in the CRP group only for the index infection episode (p = 0.007). In the per protocol analysis, involving 59 patients in each group, the median duration of antibiotic treatment was 6.0 (5.0–8.0) days for the CRP and 7.0 (7.0–10.0) days for the control (p = 0.011) groups. There was no between-group difference regarding the total days of antibiotic exposure and antibiotic-free days. CONCLUSIONS: Daily monitoring of CRP levels may allow early interruption of antibiotic therapy in a higher proportion of patients, without an effect on total antibiotic consumption. The clinical and microbiological relevance of this finding remains to be demonstrated. TRIAL REGISTRY: ClinicalTrials.gov Identifier: NCT02987790. Registered 09 December 2016.
format Online
Article
Text
id pubmed-7266125
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72661252020-06-02 Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers Borges, Isabela Carneiro, Rafael Bergo, Rafael Martins, Larissa Colosimo, Enrico Oliveira, Carolina Saturnino, Saulo Andrade, Marcus Vinícius Ravetti, Cecilia Nobre, Vandack Crit Care Research BACKGROUND: The rational use of antibiotics is one of the main strategies to limit the development of bacterial resistance. We therefore sought to evaluate the effectiveness of a C-reactive protein-based protocol in reducing antibiotic treatment time in critically ill patients. METHODS: A randomized, open-label, controlled clinical trial conducted in two intensive care units of a university hospital in Brazil. Critically ill infected adult patients were randomly allocated to (i) intervention to receive antibiotics guided by daily monitoring of CRP levels and (ii) control to receive antibiotics according to the best practices for rational use of antibiotics. RESULTS: One hundred thirty patients were included in the CRP (n = 64) and control (n = 66) groups. In the intention-to-treat analysis, the median duration of antibiotic therapy for the index infectious episode was 7.0 (5.0–8.8) days in the CRP and 7.0 (7.0–11.3) days in the control (p = 0.011) groups. A significant difference in the treatment time between the two groups was identified in the curve of cumulative suspension of antibiotics, with less exposure in the CRP group only for the index infection episode (p = 0.007). In the per protocol analysis, involving 59 patients in each group, the median duration of antibiotic treatment was 6.0 (5.0–8.0) days for the CRP and 7.0 (7.0–10.0) days for the control (p = 0.011) groups. There was no between-group difference regarding the total days of antibiotic exposure and antibiotic-free days. CONCLUSIONS: Daily monitoring of CRP levels may allow early interruption of antibiotic therapy in a higher proportion of patients, without an effect on total antibiotic consumption. The clinical and microbiological relevance of this finding remains to be demonstrated. TRIAL REGISTRY: ClinicalTrials.gov Identifier: NCT02987790. Registered 09 December 2016. BioMed Central 2020-06-01 /pmc/articles/PMC7266125/ /pubmed/32487263 http://dx.doi.org/10.1186/s13054-020-02946-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Borges, Isabela
Carneiro, Rafael
Bergo, Rafael
Martins, Larissa
Colosimo, Enrico
Oliveira, Carolina
Saturnino, Saulo
Andrade, Marcus Vinícius
Ravetti, Cecilia
Nobre, Vandack
Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers
title Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers
title_full Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers
title_fullStr Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers
title_full_unstemmed Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers
title_short Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers
title_sort duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and c-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266125/
https://www.ncbi.nlm.nih.gov/pubmed/32487263
http://dx.doi.org/10.1186/s13054-020-02946-y
work_keys_str_mv AT borgesisabela durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT carneirorafael durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT bergorafael durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT martinslarissa durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT colosimoenrico durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT oliveiracarolina durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT saturninosaulo durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT andrademarcusvinicius durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT ravetticecilia durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT nobrevandack durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers
AT durationofantibiotictherapyincriticallyillpatientsarandomizedcontrolledtrialofaclinicalandcreactiveproteinbasedprotocolversusanevidencebasedbestpracticestrategywithoutbiomarkers